Agios Pharmaceuticals, Inc.
$35.10
The Read: Agios’s stock showed modest gains on strong Pyrukynd sales and AQVESME launch updates but faced sharp declines amid legal probes overshadowing regulatory approvals, then rebounded sharply when FDA accelerated mitapivat approval and robust early sales confirmed pipeline progress.
Price
Overlays
Panel
AGIO
Hover to view data
No Data